Timothy Ko

Chief Executive Officer

Timothy Ko has a broad background of leading private ventures in the Service Sector, Investor Relations, Retail and Technology. Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of the current mental health system, and through his exposure to psychedelics which he credits with saving his life.

Brandon Schwabe, CPA, CGA

Chief Financial Officer

Brandon is a Chartered Professional Accountant (CPA, CGA) who holds a Bachelor of Technology in Accounting degree with distinction from BCIT, and has completed the Canadian Securities Course (CSC) from the Canadian Securities Institute.

Drawing on more than a decade of progressive experience guiding financial decisions and delivering solutions for companies, Brandon has extensive experience with private enterprises engaged in large capital projects, understanding the unique challenges they face.

Andrew Hegle, PhD

Director of Operations & Chief Science Officer

Dr. Andrew Hegle has been an adjunct professor of Pharmacology at the University of British Columbia since 2015. He has a background in molecular biology and biochemistry and has published research investigating the role of membrane receptor proteins in physiology, behavior and disease.

Andrew’s main professional focus has been in the creation and management of laboratory operations, and has held executive and operational management positions at several biotechnology companies, and was a cofounder of both Cannevert Therapeutics and Canalytic Laboratories in Vancouver.

Dr. Brian Jahns

Chief Business Officer

Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Entheon, including the development and maintenance of strategic relationships with third parties, including regulatory authorities. Importantly, Dr. Jahns will also work to develop a commercialization and post-market strategy for Entheon’s therapeutic protocols, while developing and advancing other related products, services, and initiatives of the company.

Yaron Eshel

Project Manager

Yaron has 15 years of experience in Life Sciences innovation. Having led efforts in product development, regulatory compliance, and operations, Yaron has worked within start-ups as well as having consulted for them.

Yaron has navigated the US, European, Israeli and Australian regulatory agencies including the registration of manufacturing facilities in the US, Central America, Israel and Australia to Good Manufacturing Practice levels. Yaron has led clinical trials in the US, Europe and Israel as well as worked with CRO’s all over the world.

Christopher Gondi, PhD

Board Member

Dr. Gondi is an Associate Professor – Departments of Medicine, Surgery and Pathology at the University of Illinois, College of Medicine, Peoria. He is a professor of cancer biology and has extensive experience dealing with brain tumors and pancreatic cancer, for which the survival rates are very low.

Christopher seeks to investigate and advance the therapeutic benefits of psychedelic-therapy for those facing mental and emotional struggles at the end of life, and how these compounds can be used to effectively treat substance-use disorder.

Ruth Chun, M.A., J.D.

Board Member

Ruth Chun is an independent director and member of the audit committee.

Ms. Chun is corporate commercial lawyer focused on advising regulated businesses in the cannabis, psychedelics and technology industries. Prior to founding Chun Law Professional Corporation, she was the general counsel and corporate secretary for Newstrike Brands Ltd. / Up Cannabis Inc. and senior legal counsel at HEXO Corp. through its acquisition of Newstrike in an all share deal valued at $346 million. Ms. Chun joined Newstrike in February 2017 and was involved in all significant corporate activity including a successful TSXV listing, debt and equity financings (exceeding $140 million), M&A, regulatory matters and government relations. She is regularly called upon as a speaker, industry expert and guest lecturer at various colleges and universities.

Ms. Chun currently serves on several boards and is the chairperson of SAVIS of Halton. She served as the first female executive at a leading insurer in southern Africa as the head of legal and compliance and was a partner at Africa’s largest law firm. Previously, she chaired Rio Tinto’s pension fund for Rössing Uranium Mine and was a trustee of the Alexander Forbes umbrella group of funds. She received an Hon BA (Trinity College), MA from the University of Toronto and Juris Doctor from Queens University. She is called to the bar in Ontario, New York and Namibia.

DuMoulin Black

Corporate Finance / M&As

Founded in 1966, DuMoulin Black has counselled hundreds of companies on the successful structuring and coordination of their corporate finance requirements and M&A needs. Having a strong relationship with investors, regulators, stock exchanges, underwriters and various industry professionals, DuMoulin Black is a trusted and effective legal partner with the track record and reputation required to navigate the modern day legal and corporate environment.

Zuber Lawler

Patents & IP

Zuber Lawler is one of the most selective law firms in the United States, with 40-plus attorneys representing clients throughout the world from offices in Chicago, Los Angeles, New York, and Silicon Valley. Our clients include more than 15 Fortune 500 clients, as well as funds and government entities. Primary practice areas include IP, regulatory work, class actions and M&A, both domestically and across languages and borders throughout the world. Zuber Lawler has attorneys trained in both common and civil law systems.

Professor Matthew W. Johnson, PhD

Scientific Advisor

Matthew Johnson is a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins, and an expert on psychoactive drugs and addiction. Matthew earned his Ph.D. in experimental psychology at the University of Vermont in 2004, has published over 110 peer-reviewed articles, and in 2008 published his psychedelic safety guidelines, which helped to resurrect and guide forthcoming psychedelic research.

Dr. Johnson has been interviewed widely by media; including 60 Minutes, New York Times, Washington Post, Wall Street Journal, BBC, CNN, NPR, and Fox Business News.

Robin Carhart-Harris, PhD

Scientific Advisor

Robin Heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College, London, where he has designed a number of functional brain imaging studies with psychedelic compounds, plus a clinical trial of psilocybin targeting treatment resistant depression. Robin has over 50 published papers in peer-reviewed scientific journals; two of which were ranked in the top 100 most impactful academic articles of 2016.

Dr Carhart-Harris obtained his PhD in Psychopharmacology from the University of Bristol, and prior to that, an MA in Psychoanalysis at Brunel University. He has an honorary position at the University of Oxford.

Dr. Dennis McKenna

Scientific Advisor

Dennis is an American ethnopharmacologist, research pharmacognosist, lecturer and author. He is the brother of well-known psychedelics proponent Terence McKenna and is a founding board member and the director of ethnopharmacology at the Heffter Research Institute. As an advisor to Entheon, he brings with him decades of research and insight.

Dr. Michael Walker

Scientific Advisor

Dr. Walker received his pharmacology training at the University of London which included a period of drug discovery training at Pfizer Ltd., (UK). Dr. Walker’s main focus has been in the discovery of drugs, both naturally occurring and synthetic, and he has developed an expertise in traversing the path to successful drug discovery.

Over the past 25 years, Dr. Walker was the founder or co-founder of eight different drug discovery companies, both public and private, including Cardiome Pharma (TSX:COM) in Canada and Verona Pharma Ltd. in London.

Christopher Timmermann, PhD

Scientific Advisor

Christopher is a psychologist educated at the Catholic University of Chile with a Masters in Neuroscience and Neuropsychological Therapy from the University of Bologna. Christopher received his PhD at the Centre for Psychedelic Research / Psychedelic Research Group, based at The Computational, Cognitive and Clinical Neuroimaging Laboratory (C3NL). His research focuses on the effects of DMT in the human brain.

Malin Vedøy Uthaug, PhD

Scientific Advisor

Completing  her PhD at the department of Neuropsychology and Psychopharmacology, at the faculty of Psychology and Neuroscience at Maastricht University, The Netherlands, Malin investigated the short-term and long-term effects of ayahuasca and 5-MeO-DMT in naturalistic setting. Malin is currently working as a Research Assistant at The Centre for Psychedelic Research, at Imperial College London, led by Dr. Robin Carhart-Harris. Here she is investigating the effects of 5-MeO-DMT on mental health related variables, brain activity and consciousness.

Kenneth W. Tupper, PhD

Advisor of Ethics

Kenneth served as an Adjunct Professor in the School of Population and Public Health at the University of British Columbia, and has been active in the field of psychedelic studies for more than fourteen years.

Kenneth is also a member of the Clinical & Scientific Advisory Board of the Multidisciplinary Association for Psychedelic Studies – Canada (MAPS-Canada) and is on the Advisory Board of the Wasiwaska Research Centre in Brazil.

Nancy Maher

Special Advisor of Data Science and Regulatory Affairs

Ms. Maher has served as an executive and consultant for major pharmaceutical and information technology companies, including IBM, Gilead, Schering-Plough, Merck, Allergan, and Teva Pharmaceuticals. Ms. Maher is currently SVP, Chief Information Officer, North America of Kyowa Kirin International plc., and joins Entheon as its Special Advisor of Data Science and Regulatory Affairs.

Ms. Maher will be consulting on the development and implementation of Entheon’s data management systems for the collection, organization and analysis of data from upcoming pre-clinical and clinical trials, partnership initiatives, private clinic partnerships, and various technological initiatives. In addition, Ms. Maher will inform the Company of best practices for the design and implementation of security measures as they relate to the Company’s data program, while also informing regulatory strategy and relationship as it relates to advancing conversations and applications with Health Canada, the FDA and EMA regulatory authorities.